Erschienen in:
08.07.2020 | COVID-19 | Brief Report
Zur Zeit gratis
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
verfasst von:
A. Cingolani, A. M. Tummolo, G. Montemurro, E. Gremese, L. Larosa, M. C. Cipriani, G. Pasciuto, R. Liperoti, R. Murri, T. Pirronti, R. Cauda, M. Fantoni, for COVID 2 Columbus Working Group
Erschienen in:
Infection
|
Ausgabe 5/2020
Einloggen, um Zugang zu erhalten
Abstract
A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.